Co-Diagnostics (DE:C970)
NASDAQ:C970
C970 Stock Chart & Stats
€0.26
-€0.13(-13.68%)
At close: 4:00 PM EST
€0.26
-€0.13(-13.68%)
Day’s Range― - ―
52-Week Range€5.16 - €36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€14.37M
Enterprise Value€3.32M
Total Cash (Recent Filing)€8.23M
Total Debt (Recent Filing)€2.03M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.26
Shares Outstanding3,685,314
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.36
Revenue Forecast (FY)€471.11K
Bulls Say, Bears Say
Bulls Say
Proprietary Platform & PipelineCo-Diagnostics' proprietary CoPrimer-based platform supports multiple assay designs and a growing pipeline (upper respiratory, TB, HPV). That technology-led diversification enables reuse of core IP across tests and instruments, improving long-term product leverage and commercialization optionality.
India Regulatory & Manufacturing FootholdRegulatory clearances plus an in-country manufacturing license and a broad distributor/lab footprint give Co-Diagnostics durable access to a large South Asia market. Local manufacturing and existing customer relationships materially lower market-entry friction and can accelerate regional revenue recovery if executed.
Low Financial LeverageModest debt reduces insolvency risk and preserves borrowing capacity, giving management flexibility to pursue bridge financing or asset-backed debt rather than immediate equity dilution. This balance-sheet headroom is a durable structural advantage when funding manufacturing or regulatory milestones.
Bears Say
Severe Revenue ContractionA tiny current revenue base versus historical scale signals lost commercial traction and underutilized fixed costs. Rebuilding sustainable sales will require successful regulatory approvals, scaled manufacturing and reestablishing distribution — a multi-quarter structural challenge with high execution effort.
Persistent Negative Operating Cash FlowChronic negative OCF at this magnitude far outstrips current sales, meaning internal cash cannot fund development and commercialization. Continued burn erodes runway, forces financing or cutbacks, and constrains strategic options — a sustained fundamental weakness unless cash flow reverses.
Capital Shortfall And Execution RiskSub-$10M cash, ongoing operating losses and unfinished manufacturing/strategic transactions create a durable execution risk: missed timelines or unfavorable financing could delay revenue ramps, dilute shareholders, or force concessions in partnerships, undermining commercialization plans.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.
What is Co-Diagnostics’s market cap?
Co-Diagnostics’s market cap is €14.37M.
When is Co-Diagnostics’s upcoming earnings report date?
Co-Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.
How were Co-Diagnostics’s earnings last quarter?
Co-Diagnostics released its earnings results on May 14, 2026. The company reported -€3.518 earnings per share for the quarter, missing the consensus estimate of N/A by -€3.518.
Is Co-Diagnostics overvalued?
According to Wall Street analysts Co-Diagnostics’s price is currently Overvalued.
Does Co-Diagnostics pay dividends?
Co-Diagnostics does not currently pay dividends.
What is Co-Diagnostics’s EPS estimate?
Co-Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Co-Diagnostics have?
Co-Diagnostics has 3,685,314 shares outstanding.
What happened to Co-Diagnostics’s price movement after its last earnings report?
Co-Diagnostics reported an EPS of -€3.518 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics
Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company that designs, produces, and globally markets specialized reagents. These components are integral to diagnostic tests that identify and analyze nucleic acid molecules. The company's product portfolio features the Co-Dx PCR platform, enabling Polymerase Chain Reaction (PCR) testing for patients in both clinical (point-of-care) and home settings. They offer an extensive range of PCR diagnostic tests for numerous conditions, including COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. Beyond human health, Co-Diagnostics develops three distinct multiplexed tests for screening mosquitos to detect disease-carrying pathogens. Their advanced molecular tools also serve broader applications, encompassing infectious disease detection, liquid biopsy for cancer screening, and agricultural uses such as identifying genetic traits in plant and animal genomes. Complementing these offerings is a portable diagnostic device, specifically engineered to make PCR testing accessible directly to patients in various settings. The company was founded in 2013 and is based in Salt Lake City, Utah.
C970 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful operational and regulatory progress across multiple strategic fronts — completed upper respiratory enrollment (>1,400 patients), India manufacturing license and expanded TAM (~$13B), TB clinical start timing, land allocation in Saudi Arabia, and manufacturing automation plans (~4x efficiency). However, the company still reports very limited absolute revenue, a negative gross margin, widening net loss and adjusted EBITDA losses, and a substantial cash decline to $8.2M with an anticipated need for additional capital. Program-level uncertainties (COVID prevalence affecting submission scope), unfinished manufacturing rollouts and no assurance on strategic transactions temper the positive operational milestones. Overall, operational momentum is clear, but financial constraints and execution risks balance the outlook.View all DE:C970 earnings summariesSintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Options Prices
Currently, No data available
---